Dicot Pharma starts Phase 2b trial of erectile dysfunction drug
Dicot Pharma has started a Phase 2b clinical trial of LIB-01, its investigational treatment for erectile dysfunction, with the study designed to evaluate repeated dosing and establish dose selection ahead of Phase 3.
The study will involve at least 200 participants in the US and Europe and assess three dose levels, including two previously evaluated in Phase 2a.
The first part of the trial has begun in the US, following the first screening visit. This stage will establish the highest dose to be evaluated in the second part, which is expected to begin after completion of Part 1 during the first quarter of 2027.
Study will assess repeated monthly dosing
The adaptive Phase 2b study will evaluate LIB-01 following repeated monthly administration in men with different severities of erectile dysfunction.
The planned doses are 25 mg and 50 mg, which demonstrated proof-of-concept in Phase 2a, alongside a higher dose to be determined during the initial part of the study.
The primary efficacy endpoint is change from baseline in the International Index of Erectile Function erectile function domain (IIEF-EF) score at week 12.
The results are intended to provide data to guide dose selection for the subsequent Phase 3 programme.
Dicot Pharma chief executive officer Elin Trampe said: “The start of our clinical study is an important milestone for the company. The Phase IIb study is tailored to LIB-01’s unique pharmacology and response profile, and we now look forward to taking the next step in the development toward a new treatment option for men and couples affected by erectile dysfunction.”
Dicot targets longer-lasting erectile dysfunction treatment
LIB-01 is being developed as a potential treatment for erectile dysfunction and premature ejaculation.
Dicot aims to develop a treatment with a longer duration of effect and fewer side effects than currently available medicines. These remain development objectives rather than established clinical benefits.
The company plans to evaluate industrial and financial partnerships during clinical development to support the potential commercialisation of LIB-01.




